Company intelligence / Profile preview

Alector

South San Francisco, California, United Statesalector.com ↗

Ownership: Public · ALEC
Employees: ~100
Development stage: Phase 3

Overview

Alector has advanced its lead candidate AL001 to a global Phase 3 trial for FTD-GRN. AL101 is in Phase 2 for Alzheimer’s disease. Preclinical programs target additional neurodegenerative diseases. The company leverages immunology and neurology insights to develop first-in-class therapies that modulate immune activity in the brain. Early clinical data have shown normalization of progranulin levels and promising safety/biomarker results.

Therapeutic areas: Neurology
Modalities: Antibody therapeutics (monoclonal antibodies)protein replacement therapies
Industry: Biotech

Drug pipeline

22 assets

latozinemab

21 more assets in the full pipeline.

Request access →

Partnerships

GSK for development of AL101Adimab for R&D of additional antibodiesFormer partnership with AbbVie on Alzheimer's program ended July 2022Johnson & Johnson Innovation Center collaboration on early research targets

Financials

Market cap: $252M
Total revenue: $3.3M
Enterprise value: $112M

Beyond the preview

Go deeper on Alector.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alector.

Explore the full profile